These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25301256)

  • 1. Inhibition of heat shock protein 90 with AUY922 represses tumor growth in a transgenic mouse model of islet cell neoplasms.
    Fendrich V; Wichmann S; Wiese D; Waldmann J; Lauth M; Rexin P; L-Lopez C; Schlitt HJ; Bartsch DK; Lang SA
    Neuroendocrinology; 2014; 100(4):300-9. PubMed ID: 25301256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms.
    Fendrich V; Wiese D; Waldmann J; Lauth M; Heverhagen AE; Rehm J; Bartsch DK
    Ann Surg; 2011 Nov; 254(5):818-23; discussion 823. PubMed ID: 22042473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
    Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
    Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.
    Moser C; Lang SA; Hackl C; Wagner C; Scheiffert E; Schlitt HJ; Geissler EK; Stoeltzing O
    Anticancer Res; 2012 Jul; 32(7):2551-61. PubMed ID: 22753713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells.
    Liu J; Sun W; Dong W; Wang Z; Qin Y; Zhang T; Zhang H
    Biochem Biophys Res Commun; 2017 May; 487(2):313-319. PubMed ID: 28412368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
    Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922.
    Bergstrom M; Monazzam A; Razifar P; Ide S; Josephsson R; Langstrom B
    J Nucl Med; 2008 Jul; 49(7):1204-10. PubMed ID: 18552146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.
    Terwisscha van Scheltinga AG; Berghuis P; Nienhuis HH; Timmer-Bosscha H; Pot L; Gaykema SB; Lub-de Hooge MN; Kosterink JG; de Vries EG; Schröder CP
    Eur J Cancer; 2014 Sep; 50(14):2508-16. PubMed ID: 25027745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.
    Cheng W; Ainiwaer A; Xiao L; Cao Q; Wu G; Yang Y; Mao R; Bao Y
    Mol Med Rep; 2015 Aug; 12(2):2451-6. PubMed ID: 25955495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer.
    Yeramian A; García V; Bergadà L; Domingo M; Santacana M; Valls J; Martinez-Alonso M; Carceller JA; Cussac AL; Dolcet X; Matias-Guiu X
    Mol Imaging Biol; 2016 Aug; 18(4):545-56. PubMed ID: 26604096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.
    Garon EB; Finn RS; Hamidi H; Dering J; Pitts S; Kamranpour N; Desai AJ; Hosmer W; Ide S; Avsar E; Jensen MR; Quadt C; Liu M; Dubinett SM; Slamon DJ
    Mol Cancer Ther; 2013 Jun; 12(6):890-900. PubMed ID: 23493311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma.
    Kosovec JE; Zaidi AH; Kelly LA; Rotoloni CL; Vytlacil C; DiCarlo C; Matsui D; Komatsu Y; Boyd NH; Omstead A; Kolano EL; Biederman RW; Finley G; Silverman JF; Landreneau RJ; Jobe BA
    Ann Surg; 2016 Aug; 264(2):297-304. PubMed ID: 26445473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors.
    Bendell JC; Bauer TM; Lamar R; Joseph M; Penley W; Thompson DS; Spigel DR; Owera R; Lane CM; Earwood C; Burris HA
    Cancer Invest; 2016 Jul; 34(6):265-70. PubMed ID: 27379708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
    Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
    Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.
    Mayer P; Harjung A; Breinig M; Fischer L; Ehemann V; Malz M; Scherübl H; Britsch S; Werner J; Kern MA; Bläker H; Schirmacher P; Bergmann F
    Endocr Relat Cancer; 2012 Jun; 19(3):217-32. PubMed ID: 22194440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.